Capital International Sarl Has $7.36 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital International Sarl lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 186,920 shares of the company's stock after buying an additional 16,397 shares during the quarter. Capital International Sarl owned about 0.22% of CRISPR Therapeutics worth $7,357,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Intellectus Partners LLC lifted its stake in CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock worth $281,000 after acquiring an additional 250 shares during the period. Farrow Financial Inc. raised its holdings in CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock worth $777,000 after acquiring an additional 270 shares during the last quarter. Kestra Private Wealth Services LLC lifted its holdings in shares of CRISPR Therapeutics by 1.5% during the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock valued at $812,000 after purchasing an additional 310 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of CRISPR Therapeutics by 7.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock worth $215,000 after acquiring an additional 372 shares during the period. Finally, Horizon Kinetics Asset Management LLC grew its holdings in shares of CRISPR Therapeutics by 4.3% in the fourth quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company's stock worth $420,000 after acquiring an additional 443 shares during the period. 69.20% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on CRSP shares. Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price target for the company from $60.00 to $99.00 in a report on Friday, February 14th. Bank of America reduced their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Stifel Nicolaus cut their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research report on Thursday, February 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, April 9th. Finally, Citigroup decreased their price objective on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics has an average rating of "Hold" and an average price target of $73.11.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock traded up $0.05 during mid-day trading on Monday, reaching $37.82. The company's stock had a trading volume of 1,652,839 shares, compared to its average volume of 1,631,378. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $67.88. The company has a market cap of $3.24 billion, a P/E ratio of -8.65 and a beta of 1.85. The firm's 50-day moving average is $40.93 and its two-hundred day moving average is $43.73.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Buying and Selling

In related news, COO Julianne Bruno sold 1,198 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at approximately $350,516.46. This represents a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the sale, the chief executive officer now owns 180,890 shares of the company's stock, valued at approximately $7,673,353.80. This represents a 5.23 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.